Triple reuptake inhibitor
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor whose plasma half-life is described in a 2026 report as "in excess of 200 h"; the app lists 220 hours, about 9.2 days.1
Tesofensine after one dose: 50% at ~220 h, 25% at 440 h, 12.5% at 660 h.
Drawn from the half-life in the app's model, ~220 h. The model's figures
- Compound
- Tesofensine
- Symbol
- TSO
- Family
- Metabolic and mitochondrial peptides
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Tesofensine (also written NS-2330) is described in a 2026 anti-doping study as a centrally acting triple monoamine reuptake inhibitor that blocks the presynaptic reuptake of dopamine, norepinephrine and serotonin.1 The same report says it was "initially developed for neurodegenerative disorders" and "subsequently repositioned as a potential" anti-obesity drug.1 The report also states that it has been "marketed online as a dietary supplement promoted for weight management and metabolic enhancement" despite "the absence of full marketing authorization".1
The app grades the evidence for tesofensine as emerging. The human evidence read for this compound is a set of phase 2 trials in obesity, Parkinson disease and Alzheimer disease, a single-dose abuse-liability study, a pharmacokinetic model and registry entries for later studies of tesofensine with metoprolol. The registry lists NeuroSearch A/S as lead sponsor of the 2006–2007 obesity trial and of the 2007 long-term safety study, and Saniona as lead sponsor of the later studies combining tesofensine with metoprolol.3,4,5,6,7
How it works
Sources in this part
Astrup and colleagues describe tesofensine as "an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin".2 Krug and colleagues add that enhanced monoaminergic neurotransmission modulates hypothalamic appetite-regulating circuits, a mechanism they cite from earlier work and did not test themselves.1 In people, the one study read that measured appetite sensations in a drug-free and a re-treated state is the phase 2 obesity programme reported by Gilbert and colleagues (Obesity, 2012).8 In Part 1 of that programme, "TE induced a dose-dependent increase in CSS", a composite satiety score, at week 12.8 The score then "diminished over time as weight loss progressed", returned to baseline values after drug withdrawal and rose again when tesofensine was reintroduced in the open-label Part 2.8 The authors write that whether the attenuated effect after 24 weeks reflects a counteracting effect in the weight-reduced state or a diminishing appetite-suppressing effect of tesofensine "is, however, still unclear".8 The record read gives no funding or disclosure statement for this study, PubMed tags it "Research Support, Non-U.S. Gov't", and Part 2 had no control group.8 Animal and cell findings on tesofensine's brain targets are not described, because the sources used cover human studies.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~220 h
- Bioavailability
- 90%
- Typical dose
- 0.25–1 mg/day
- Route
- Oral
- Time to peak
- ~10 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~220 h (about 9.2 days) | The 2026 urine study states a plasma half-life "in excess of 200 h", in its introduction and without a fitted value; the app's figure is 220 h1 |
| Bioavailability | 90% | None of the human sources read reports an absolute oral bioavailability; the app's figure of 90% therefore has no figure from the sources beside it |
| Time to peak | ~10 h | Registry geometric mean time of maximum concentration of 6.12 h (high-dose fixed-dose tablet with 1 mg tesofensine, fasted), 6.00 h (low-dose tablet with 0.2 mg tesofensine, fasted), 6.00 h (comparator tablets with 1 mg tesofensine, fasted) and 8.00 h (high dose, fed), single dose, 15 healthy men per group, for tesofensine and metoprolol as the outcome is defined; the app's figure is 10 h5 |
| Model | One compartment | A three-compartment model (absorption, central and gallbladder) with first-order elimination described plasma profiles after a single 6-hour intravenous infusion in 21 healthy subjects9 |
| Urine | Not an app field | Peak urinary concentrations of 1-4 ng/mL after 4-46 h and detection windows up to 500 h in six volunteers after a single 483 μg oral dose taken as a dietary supplement; windows exceeding 500 h in some individuals were reported for several metabolites1 |
Lehr and colleagues (Clinical Pharmacokinetics, 2009) analysed two earlier studies retrospectively, one of tesofensine and one of meloxicam, and report that a three-compartment model with a gallbladder compartment described the multiple peaks in tesofensine's plasma profiles, with enterohepatic circulation "suspected" for tesofensine.9 The tesofensine data used for the model came from a single 6-hour intravenous infusion study in 21 healthy subjects (0.3, 0.6, 0.9 and 1.2 mg), and the record names no sponsor for that study.9 Krug and colleagues (Drug Testing and Analysis, 2026) tentatively identified "four principal metabolites" in urine: three dealkylated and one hydroxylated and glucuronidated.1 They note "marked interindividual variability" in a group of six, and their work was funded by grants from the Manfred-Donike Institute for Doping Analysis and the Federal Ministry of the Interior and Community.1 The sources read give no plasma elimination half-life fitted from an oral study, so the app's 220 hours cannot be set against a measured oral value here.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Astrup and colleagues, Lancet 20082 | Phase II, randomised, double-blind, placebo-controlled, five Danish centres; lead sponsor on the registry NeuroSearch A/S2,3 | 203 obese patients (BMI 30 to 40 kg/m2) on an energy-restricted diet; 161 (79%) completed2 | Tesofensine 0.25 mg (n=52), 0.5 mg (n=50), 1.0 mg (n=49) or placebo (n=52) once daily for 24 weeks2 | Weight loss beyond diet and placebo (2.0%) of 4.5%, 9.2% and 10.6% at the three doses; heart rate up 7.4 beats per min at 0.5 mg, with no significant blood pressure increase at 0.25 mg and 0.5 mg; dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia most common; the Lancet published an expression of concern about the trial in 2013, and the authors a letter titled "Under-reporting of adverse effects of tesofensine"2,13,14 |
| Gilbert and colleagues, Obesity 20128 | Phase II in two 24-week parts: Part 1 randomised, double-blind, placebo-controlled; Part 2 open-label, single-group, uncontrolled, after a drug-free period8 | Part 1: 158 participants; Part 2: 113 completers of Part 18 | Part 1: 0.25, 0.5 or 1.0 mg or placebo; Part 2: 0.5 or 1.0 mg8 | Composite satiety score rose with dose at week 12, diminished by week 24, returned to baseline after withdrawal and rose again on re-treatment8 |
| Registry entry NCT00481104, NeuroSearch A/S, 2007–20084 | Phase 2, single group, no masking, long-term safety4 | 140 people with obesity who had completed participation in a study the entry calls TIPO-1 (listed enrolment, actual)4 | Tesofensine; dose and length not stated in the entry4 | The entry as read shows no posted results4 |
| Astrup and colleagues, Obesity 2008 (meta-analysis)10 | Four randomised, double-blind, multicentre trials in Parkinson or Alzheimer disease, pooled; no weight-loss programme; results adjusted for baseline values, age and study10 | 740 on tesofensine and 228 on placebo; 21% of the tesofensine group and 14% of the placebo group were obese10 | 0.125, 0.25, 0.5 or 1.0 mg once daily for 14 weeks10 | Total cohort weight change +0.5% (placebo), -0.5, -0.9, -1.8 and -2.8% across the doses; obese subgroup -0.2% (placebo), -1.7, -1.6, -1.5 and -3.7%; heart rate change -0.4 (placebo), 2.1, 4.2, 6.0 and 6.8 bpm; no effect on blood pressure was observed10 |
| Rascol and colleagues, Archives of Neurology 2008 (ADVANS)11 | Pilot phase 2, randomised, double-blind, placebo-controlled, parallel-group11 | Patients with advanced Parkinson disease and levodopa-related motor fluctuations11 | 0.125, 0.25, 0.5 or 1 mg once daily for 14 weeks11 | Versus placebo: -4.7 points on the UPDRS II plus III total at 0.5 mg and -7.1% off time at 0.25 mg; other doses not significant; gastrointestinal tract and neuropsychiatric adverse events were more frequent than with placebo, especially at the higher dosages; the authors state a dose-response relationship could not be established for efficacy11 |
| Schoedel and colleagues, Clinical Pharmacology and Therapeutics 201012 | Single-dose, randomised, double-blind, crossover against placebo, D-amphetamine, bupropion and atomoxetine12 | 52 recreational stimulant users12 | Single dose; measures for 48 h; tesofensine dose not stated in the record read12 | Tesofensine effects not significantly different from placebo and lower than D-amphetamine 30 mg on all primary and most secondary measures12 |
| Registry entry NCT03488719, Saniona6 | Phase 1, tesofensine with single-blind metoprolol; halted and then ended early6 | 37 subjects enrolled before the halt6 | Tesofensine 0.25, 0.50 or 0.75 mg once daily in three cohorts, with metoprolol on set days6 | Two subjects in cohort 2 had prolonged tachycardia, a stopping criterion; the sponsor ended the trial on 20 February 20196 |
| Registry entry NCT02737891, Saniona, 2016–20177 | Double-blind, randomised, placebo-controlled, multiple-dose, two-centre, with metoprolol in the active arm7 | 60 people with type 2 diabetes mellitus, 30 per arm7 | Tesofensine 0.5 mg plus metoprolol 100 mg or placebo; baseline to day 907 | Net 24-hour mean heart rate -3.8 bpm (95% CI -6.36 to -1.29), body weight -3.5 kg (95% CI -4.65 to -2.30), HbA1c difference 0.1 (p 0.724)7 |
Deeper analysis: the 24-week obesity trial (Astrup and colleagues, Lancet 2008)
Astrup and colleagues, based at the University of Copenhagen and Danish hospitals, reported a phase II trial of tesofensine in 203 obese patients in the Lancet in 2008.2 Patients had a 2-week run-in, then an energy-restricted diet and random assignment to tesofensine 0.25 mg (n=52), 0.5 mg (n=50), 1.0 mg (n=49) or placebo (n=52) once daily for 24 weeks, with percentage change in bodyweight as the primary outcome.2 Analysis was by "modified intention to treat", meaning all randomised patients with a measurement after at least one dose.2 In the findings, 161 (79%) participants completed the study; diet and placebo gave a mean loss of 2.0% (SE 0.60), and the three tesofensine doses produced 4.5% (0.87), 9.2% (0.91) and 10.6% (0.84) "greater than diet and placebo" (p<0.0001).2 On safety, the record states that "the most common adverse events caused by tesofensine were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia".2 At 0.25 mg and 0.5 mg there were "no significant increases in systolic or diastolic blood pressure compared with placebo", while heart rate rose by 7.4 beats per min at 0.5 mg (p=0.0001).2 The record gives no blood pressure or heart rate comparison for the 1.0 mg group, no discontinuation counts by arm and no secondary results on body composition or quality of life, although both appear in the title.2 The authors conclude that 0.5 mg "might have the potential to produce a weight loss twice that of currently approved drugs" and that "these findings of efficacy and safety need confirmation in phase III trials".2 The record names no funder; PubMed tags it "Research Support, Non-U.S. Gov't", and the registry entry names NeuroSearch A/S, a company, as lead sponsor, with Arne Astrup as principal investigator.2,3 The registry lists Arne Astrup, an author of the report, as principal investigator of this industry-sponsored trial; neither the PubMed record nor the registry entry carries a disclosure statement or a funding statement for the authors. The registry lists an estimated enrolment of 200, against the 203 randomised in the report.3 In 2013 the Lancet published an "Expression of Concern" about this trial, and the trial's authors published a letter titled "Under-reporting of adverse effects of tesofensine".13,14 Neither PubMed record carries text, so the reasons and the content of the letter are not reported here.13,14
Deeper analysis: the metoprolol combination studies (Saniona)
Saniona registered phase 1 and 2 studies of tesofensine with metoprolol, a combination the entries call Tesomet or tesofensine/metoprolol.5,7 The heart-rate study states its rationale: heart rate "has been shown to be the most affected safety endpoint by the effects of tesofensine".6 In that study tesofensine was given once daily for 23 days in three cohorts: 0.25 mg after a 1.0 mg loading dose for the first 3 days (cohort 1), 0.50 mg after a 2.0 mg loading dose for the first 3 days (cohort 2) and 0.75 mg after a 2.0 mg loading dose for the first 5 days (cohort 3), with metoprolol extended release 25, 50 or 100 mg in random order on days 15, 18 and 21.6 After 37 subjects were enrolled, two in cohort 2 had tachycardia above 120 beats per minute lasting 30 min, "a stopping criteria of the study", and the study was halted on 22 November 2018.6 The sponsor reviewed the data from completed participants, judged them "sufficiently robust to answer the questions for which the trial was designed" and ended the trial permanently on 20 February 2019.6 The registry lists no deaths, serious adverse events in 0 of 9 on 0.25 mg, 1 of 16 on 0.50 mg and 1 of 12 on 0.75 mg, and other adverse events in 7 of 9, 15 of 16 and 12 of 12 respectively, reported per tesofensine dose group.6 In the type 2 diabetes study, 30 people took tesofensine 0.5 mg with metoprolol 100 mg and 30 took placebo, for 90 days.7 The posted primary outcome, 24-hour mean heart rate, differed by a net -3.8 bpm (95% CI -6.36 to -1.29; p 0.004) between the combination and placebo, which is the combination's effect and not that of tesofensine alone.7 Body weight changed by a net -3.5 kg (95% CI -4.65 to -2.30), and the HbA1c difference was 0.1 (95% CI -0.23 to 0.33; p 0.724), so no HbA1c difference was shown.7 The registry lists no deaths in either arm, no serious adverse events with the combination, one with placebo, and other adverse events in 20 of 30 on the combination and 12 of 30 on placebo.7 These are registry records written by the sponsor; no peer-reviewed report of these studies was read, so no author-stated limitations are available.
Doses reported in studies and on labels
A search of DailyMed for tesofensine returned no labels, and the doses below come from studies. The app's typical range is 0.25 to 1 mg per day by mouth, which matches the once-daily doses used in the phase 2 trials.
| Source | Dose | Comparator and population | Length and n |
|---|---|---|---|
| Astrup and colleagues 20082 | 0.25, 0.5 or 1.0 mg once daily | Placebo; obese patients on a diet | 24 weeks; 203 |
| Gilbert and colleagues 2012, Part 1 and Part 28 | 0.25, 0.5 or 1.0 mg; Part 2 0.5 or 1.0 mg | Placebo in Part 1; Part 2 uncontrolled | 24 weeks per part; 158 and 113 |
| Astrup and colleagues 2008 (meta-analysis)10 | 0.125, 0.25, 0.5 or 1.0 mg once daily, oral | Placebo; Parkinson or Alzheimer disease | 14 weeks; 740 and 228 |
| Rascol and colleagues 200811 | 0.125, 0.25, 0.5 or 1 mg once daily | Placebo; advanced Parkinson disease | 14 weeks; n not stated in the record read |
| NCT027378917 | Tesofensine 0.5 mg plus metoprolol 100 mg | Placebo; type 2 diabetes | 90 days; 60 |
| NCT034887196 | 0.25, 0.50 or 0.75 mg once daily plus metoprolol | No placebo arm; cohorts | 23 days (0.25 mg arm); 37 |
| NCT032868295 | Single dose: 1 mg tesofensine in the high-dose fixed-dose tablet and in the comparator, 0.2 mg in the low-dose tablet, each with metoprolol | Four groups of healthy men, fasted and fed | Single dose; 15 per group |
Side effects reported
In the 24-week obesity trial the most common adverse events caused by tesofensine were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia.2 In advanced Parkinson disease, "gastrointestinal tract and neuropsychiatric adverse events were more frequent with tesofensine than with placebo, especially at the higher dosages".11 In the pooled Parkinson and Alzheimer trials, heart rate changes were -0.4 bpm with placebo and 2.1, 4.2, 6.0 and 6.8 bpm across the four doses, with no effect on blood pressure observed.10 A heart-rate interaction study with metoprolol was halted after two subjects had prolonged tachycardia above 120 beats per minute.6 In the 2013 letter title, the authors of the obesity trial refer to "Under-reporting of adverse effects of tesofensine"; the text of the letter was not read.14 In a single-dose study in recreational stimulant users, the authors concluded that "tesofensine is therefore unlikely to be recreationally abused".12 That study gave single doses, so it speaks to abuse-related effects and not to adverse events over weeks.12 The record read gives no funding or disclosure statement for this study and does not state the tesofensine dose tested.12
Bloodwork and markers
Sources in this part
The app lists blood pressure and heart rate as the markers to monitor. Across the human sources read, heart rate is the marker that rose with tesofensine: by 7.4 beats per min at 0.5 mg in the obesity trial and by 2.1 to 6.8 bpm across doses in the pooled neurodegenerative-disease trials.2,10 Blood pressure showed no significant increase at 0.25 mg and 0.5 mg in the obesity trial, and no effect in the pooled trials.2,10 The registry lists HbA1c and body weight as outcomes in the diabetes study, with the HbA1c difference 0.1 (95% CI -0.23 to 0.33).7
Regulatory and anti-doping status
Sources in this part
Krug and colleagues state that, "despite the absence of full marketing authorization", tesofensine-containing products are sold online as dietary supplements.1 A DailyMed search for tesofensine returned no labels, and EMA and TGA documents were not searched. The 2026 WADA Prohibited List names tesofensine among the specified stimulants in section S6, which is headed "prohibited in-competition".15 Krug and colleagues likewise write that it "is prohibited in-competition only" and report urinary detection windows up to 500 h in six volunteers after a single 483 μg oral dose, with windows exceeding 500 h in some individuals for several metabolites.1
What is not known
The sources read do not give an absolute oral bioavailability, a fitted oral plasma half-life or a volume of distribution for tesofensine. No phase 3 trial of tesofensine was identified among the 13 ClinicalTrials.gov records returned for "tesofensine", which list phase 1, phase 1/2 and phase 2 studies. The Astrup trial's authors write that its findings need confirmation in phase III trials, and the Lancet later published an expression of concern about it.2,13 The appetite findings leave open whether the fading effect on appetite reflects the weight-reduced state or the drug itself.8 The metoprolol combination studies are known here only through registry entries, and a report in the PubMed records read was not identified.
Frequently asked questions
What drug class is tesofensine?
Tesofensine is described as a centrally acting triple monoamine reuptake inhibitor of dopamine, norepinephrine and serotonin.1
Is tesofensine banned by WADA?
The 2026 WADA Prohibited List names tesofensine under the specified stimulants in S6, which is prohibited in-competition.15
Is tesofensine approved?
Krug and colleagues refer to "the absence of full marketing authorization" for tesofensine.1 A DailyMed search for tesofensine returned no labels.
How much weight loss did tesofensine produce in the phase 2 obesity trial?
In the 24-week trial in 203 obese patients, the 0.25, 0.5 and 1.0 mg doses with diet gave 4.5%, 9.2% and 10.6% weight loss greater than diet and placebo, which gave 2.0%.2 Its authors state that the findings need confirmation in phase III trials, and 161 (79%) completed the study.2 In the same trial heart rate rose by 7.4 beats per min at 0.5 mg, and the Lancet published an expression of concern about it in 2013.2,13
How long can tesofensine be detected in urine?
In six volunteers after a single 483 μg oral dose taken as a supplement, detection windows reached up to 500 h, with windows exceeding 500 h in some individuals for several metabolites.1
How long does tesofensine take to reach its peak level?
Does tesofensine have abuse potential?
A single-dose study in 52 recreational stimulant users concluded that its abuse potential is "no greater than that of bupropion or atomoxetine".12
Guides, tools and comparisons
References
- Krug O, Thomas A, Thevis M. Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. Drug Test Anal 2026. Krug 2026
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008. PMID 18950853
- NeuroSearch A/S. Effect of Tesofensine on Weight Reduction in Patients With Obesity. ClinicalTrials.gov NCT00394667. NCT00394667
- NeuroSearch A/S. Evaluation of Long Term Safety of Tesofensine in Patients With Obesity. ClinicalTrials.gov NCT00481104. NCT00481104
- Saniona. Study to Investigate the Pharmacokinetic Profile (tesofensine and metoprolol fixed-dose tablet). ClinicalTrials.gov NCT03286829. NCT03286829
- Saniona. A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate. ClinicalTrials.gov NCT03488719. NCT03488719
- Saniona. Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus. ClinicalTrials.gov NCT02737891. NCT02737891
- Gilbert JA, et al. The effect of tesofensine on appetite sensations. Obesity (Silver Spring) 2012. PMID 21720440
- Lehr T, et al. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet 2009. PMID 19705923
- Astrup A, et al. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008. PMID 18356831
- Rascol O, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008. PMID 18474731
- Schoedel KA, et al. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010. PMID 20520602
- Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet 2013;381:1167. PMID 23561987
- Astrup A, et al. Under-reporting of adverse effects of tesofensine. Lancet 2013;382:127. PMID 23849924
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list